Abstract | Background: Methods: DRIVE-AHEAD is a phase 3, double-blind, non-inferiority trial. Antiretroviral treatment-naive adults with ≥1000 HIV-1 RNA copies/mL were randomized (1:1) to once-daily, fixed-dose DOR at 100 mg, lamivudine at 300 mg, and tenofovir disoproxil fumarate (TDF) at 300 mg (DOR/3TC/TDF) or to efavirenz at 600 mg, emtricitabine at 200 mg, and TDF at 300 mg (EFV/ FTC/TDF) for 96 weeks. The primary efficacy endpoint was the proportion of participants with <50 HIV-1 RNA copies/mL at week 48 (Food and Drug Administration snapshot approach; non-inferiority margin 10%). Results: Of the 734 participants randomized, 728 were treated (364 per group) and included in the analyses. At week 48, 84.3% (307/364) of DOR/3TC/TDF recipients and 80.8% (294/364) of EFV/ FTC/TDF recipients achieved <50 HIV-1 RNA copies/mL (difference 3.5%, 95% CI, -2.0, 9.0). DOR/3TC/TDF recipients had significantly lower rates of dizziness (8.8% vs 37.1%), sleep disorders/disturbances (12.1% vs 25.2%), and altered sensorium (4.4% vs 8.2%) than EFV/ FTC/TDF recipients. Mean changes in fasting low-density lipoprotein cholesterol ( LDL-C) and non- high-density lipoprotein cholesterol (non-HDL-C) were significantly different between DOR/3TC/TDF and EFV/ FTC/TDF (-1.6 vs +8.7 mg/dL and -3.8 vs +13.3 mg/dL, respectively). Conclusions: In HIV-1 treatment-naive adults, DOR/3TC/TDF demonstrated non-inferior efficacy to EFV/ FTC/TDF at week 48 and was well tolerated, with significantly fewer neuropsychiatric events and minimal changes in LDL-C and non-HDL-C compared with EFV/ FTC/TDF. Clinical Trials Registration: NCT02403674.
|
Authors | Chloe Orkin, Kathleen E Squires, Jean-Michel Molina, Paul E Sax, Wing-Wai Wong, Otto Sussmann, Richard Kaplan, Lisa Lupinacci, Anthony Rodgers, Xia Xu, Gina Lin, Sushma Kumar, Peter Sklar, Bach-Yen Nguyen, George J Hanna, Carey Hwang, Elizabeth A Martin, DRIVE-AHEAD Study Group |
Journal | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
(Clin Infect Dis)
Vol. 68
Issue 4
Pg. 535-544
(02 01 2019)
ISSN: 1537-6591 [Electronic] United States |
PMID | 30184165
(Publication Type: Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-HIV Agents
- RNA, Viral
- Reverse Transcriptase Inhibitors
|
Topics |
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Anti-HIV Agents
(administration & dosage)
- Antiretroviral Therapy, Highly Active
(methods)
- Double-Blind Method
- Female
- HIV Infections
(drug therapy, virology)
- HIV-1
(isolation & purification)
- Humans
- Male
- Middle Aged
- RNA, Viral
(blood)
- Reverse Transcriptase Inhibitors
(administration & dosage)
- Treatment Outcome
- Viral Load
- Young Adult
|